The James Buchanan Brady Urological Institute
  • Dr. Pienta envisions new drugs for cancer that has recurred following definitive therapy with surgery and radiation, as well as effective medications for more advanced hormone-refractory disease... Read more

  • Dr. Stoianovici research is focused on the design, manufacturing, and control of robots for direct image-guided intervention (DIGI)... Read more

  • The Fisher Biomarker laboratories are engaged in biomarker research and development to improve the early detection, staging, monitoring, and prognosis of prostate cancer (PCa) and other urologic cancers... Read more

  • Prevention ... Cure ... Improved symptom management ... Quality of life renewal... Read more

  • The laboratory focuses on biological mechanisms of the pelvis as these relate to erectile and voiding dysfunctions primarily Read more

  • The mission of our laboratory is to study the biology of urologic malignancies, particularly prostate cancer, and to use this information to foster the development of new experimental diagnostic, prognostic, and therapeutic agents. Read more

Clinical Trials
Contact Info

Among other achievement, our scientists at the Brady Urological Institute have:

  • Developed the radical prostatectomy.
  • Developed "nerve-sparing" approaches for radical prostatectomy and cystectomy.
  • Pioneered the laparoscopic live donor nephrectomy, a procedure that has revolutionized kidney transplantation.
  • First telerobotic mentoring system utilizing public phone lines.
  • Developed the first endoscopic approach to transurethral resection of the prostate (TUR).
  • Developed the systems used to classify and stage prostate cancer.
  • Improved the use of PSA testing for early diagnosis and staging of prostate cancer.
  • Pioneered the first gene therapy in urology.
  • Discovered hereditary prostate cancer, and the linkage to the first hereditary prostate cancer gene.
  • Discovered- the nuclear matrix protein, a major factor that regulates DNA; Brady scientists also were the first to characterize the prostate-specific nuclear matrix.
  • Identified the most common genetic defect in prostate cancer.
  • Discovered a gene that suppresses metastasis in prostate cancer.
  • Determined the scientific basis for hormone-refractory prostate cancer (which cannot be controlled permanently with hormone therapy) - androgen-independent cells.
  • Discovered the mechanism of cancer cells'response to hormone therapy - activation of a crucial cellular pathway called programmed cell death.
  • Discovered the first mutation in an androgen-receptor gene.
  • Made the first detailed map of alpha-adrenergic receptors (involved in the treatment of BPH) in the genito-uninary tract.
  • Discovered that nitric oxide controls penile erection.
  • Discovered a means of extracting intact prostate cancer cells from the blood which may lead to new forms of treatment.
  • Characterized the role of telomerase (an enzyme that keeps cells from dying) in prostatic disease.

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.| Disclaimer
Email: | 600 North Wolfe Street, Baltimore, Maryland 21287